post hoc analysis: triple-combination subgroup GRIPHON—The FIRST and ONLY COMPLETED PAH Outcomes Trial That Included Patients Treated With TRIPLE-Combination Therapy1-3

The information below is from a post hoc subgroup analysis of the GRIPHON trial.
View the GRIPHON pivotal data for context of the overall population.

Post Hoc SUBGROUP Analysis: 37% Risk Reduction of Disease Progression in Patients TREATED WITH UPTRAVI + ERA + PDE-5i1-3

Baseline patient characteristics

  • 33% (n=376) of all patients in GRIPHON were receiving an ERA and a PDE-5i at baseline (31% FC II and 68% FC III)*
  • Etiology in triple-combination subgroup: IPAH/HPAH (64%), PAH-CTD (26%), PAH-CHD (5%), other (5%)

Notable differences from overall population

The triple-combination subgroup had:

  • Longer time from diagnosis (3.8 years vs 2.4 years in the overall population)
  • Larger percentage from Western Europe/Australia (52.9% vs 27.8%)
  • Larger percentage from North America (28.5% vs 16.7%)
Time to first disease progression event
The treatment effect was established early and maintained over the entire treatment period

Events in patients receiving ERA + PDE-5i at baseline

Adverse reactions in triple-combination subgroup notably different from overall population

  • Tolerability was generally consistent with overall population
  • The most common adverse reactions were headache, diarrhea, nausea, and jaw pain
  • Similar to the overall population, treatment-related adverse reactions were more frequent during titration

Post Hoc Subpopulation Analysis: 64% Risk Reduction of Disease Progression in FC II Patients already receiving ERA + PDE-5i1-3

Baseline patient characteristics

  • 10% (n=115) of all patients in GRIPHON were FC II and receiving an ERA and a PDE-5i at baseline
  • Etiology in FC II triple-combination subpopulation: IPAH/HPAH (70%), PAH-CTD (18%), PAH-CHD (6%), other (6%)

Notable differences from overall population

The FC II triple-combination subpopulation had:

  • Longer time from diagnosis (4 years vs 2.4 years in the overall population)
  • Larger percentage from Western Europe/Australia (43.5% vs 27.8%)
  • Larger percentage from North America (31.3% vs 16.7%)
Time to first disease progression event in FC II patients receiving ERA + PDE-5i at baseline

Events in FC II patients receiving ERA + PDE-5i at baseline

Adverse reactions in FC II triple-combination subpopulation notably different fromoverall population§

  • Tolerability was generally consistent with overall population
  • Similar to the overall population, treatment-related adverse reactions were more frequent during titration

Post Hoc Subpopulation Analysis: 26% Risk Reduction of Disease Progression in FC III Patients already receiving ERA + PDE-5i1-3

Baseline patient characteristics

  • 22% (n=255) of all patients in GRIPHON were FC III and receiving an ERA and a PDE-5i at baseline
  • Etiology in FC III triple-combination subpopulation: IPAH/HPAH (61%), PAH-CTD (29%), PAH-CHD (5%), other (4%)

Notable differences from overall population

The FC III triple-combination subpopulation had:

  • Longer time from diagnosis (3.8 years vs 2.4 years in the overall population)
  • Larger percentage from Western Europe/Australia (56.9% vs 27.8%)
  • Larger percentage from North America (27.5% vs 16.7%)
  • Older average age (52 years vs 48.1 years)
Time to first disease progression event in FC III patients receiving ERA + PDE-5i at baseline

Events in FC III patients receiving ERA + PDE-5i at baseline

Adverse reactions in FC III triple-combination subpopulation notably different fromoverall population

  • Tolerability was generally consistent with overall population
  • Similar to the overall population, treatment-related adverse reactions were more frequent during titration